Treating children with familial hypercholesterolemia (FH) early can help reduce progression of atherosclerosis without adverse events related to growth and development, said Raul Santos, MD, PhD, director, Lipid Clinic at the Heart Institute, and associate professor, University of São Paulo Medical School, Brazil.
Treating children with familial hypercholesterolemia (FH) early can help reduce progression of atherosclerosis without adverse events related to growth and development, said Raul Santos, MD, PhD, director, Lipid Clinic at the Heart Institute. and associate professor, University of São Paulo Medical School, Brazil.
Transcript
Why has early treatment of familial hypercholesterolemia with therapy been controversial?
You know, there's a lot of discussion why we should start treating kids early, right? Because usually atherosclerosis, it starts developing very early, but manifestation will be, let's say, by the age of 40, 45, 50. So, people say, “Oh, maybe you can wait for these kids to become adults and then we could start treating them.” But, actually, we have evidence that if you start treating early, like let's say, the age of 10 or even earlier, we can reduce the progression of atherosclerosis. We can use imaging techniques to show that the disease progression is much, much lower. And actually, we can even regress that. So this is one argument in favor of treating early.
Second, now we have—at least with the statins—20 years of follow-up showing the drugs are safe and they don't compromise growth, sexual development, cognitive function, and everything. And by the way, I think it's important to say that, actually, evolocumab was very safe regarding growth, sexual development, steroid hormones, lack of soluble vitamins. So, actually, we measured all of that and in the kids it was great. And with the statins, it’s the same thing. So, I think it's time to stop this controversy and start, of course, if we understand that those kids have enough risk, very high [low-density lipoprotein cholesterol], bad family history, start treatment as soon as possible.
What are the benefits and risks of early treatment?
You know, actually, lipid-lowering therapy for kids is very safe. There might be some concern that because kids might need cholesterol for growing up, for brain development, there might be some trouble with that, but this is not true. Actually, we saw in in HAUSER, we didn't see any adverse events related to growth, pubertal development…neurocognitive function. And actually, we also had seen with the statins, the same thing. So, actually, even if we put, let's say, a very powerful therapy on top of drugs that kids are already taking, we didn't see anything that is bad. Actually, we have follow-ups up to 2 years. Of course, we say 2 years is not a lifetime, but as I said, we have more than 20 years follow-up with the statins and we didn’t see any harm.
Industry Experts Tackle Specialty Drug Access Challenges for Employer Benefit Plans
May 2nd 2024Representatives from ICON plc and Symphony Health joined forces as AXS24 to discuss the challenges of managing high-cost specialty drugs and how they influence self-funded employer benefit plan design and employee access to specialty medications.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Specialty Pharmacists at the Forefront: Elevating Care for Rare Diseases
May 1st 2024In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an estimated total of 25 to 30 million Americans overall living with a rare disease at any given time.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Latest Advances and Updates of Treatment in the Real World at AUA
May 1st 2024The annual meeting of the American Urological Association (AUA) not only presents the newest therapies coming out but showcases the latest in how treatments are being used in the real world, said Stephen Freedland, MD, of Cedars Sinai.
Read More
BRCA-Like Classification May Be a Useful Biomarker for Olaparib Response in Ovarian Cancer
May 1st 2024Adding olaparib to maintenance therapy with bevacizumab was associated with significantly longer survival for patients with ovarian cancer whose tumors have a BRCA-like genomic profile, but not among those with non-BRCA-like tumors, a study found.
Read More